OncoMatch

OncoMatch/Clinical Trials/NCT07809763

Wireless Wearable Home Prehabilitation for Older Adults With NSCLC

Official title: Home-Based Prehabilitation Using Wireless Wearable Mobile Monitoring Devices for Elderly Patients With Non-Small Cell Lung Cancer

Is NCT07809763 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for non-small cell lung cancer (nsclc).

NARecruitingWest China HospitalNCT07809763Data as of Oct 2026Location: China

This randomized controlled trial evaluates the efficacy and safety of a home-based prehabilitation program using wireless wearable monitoring devices in older patients (aged 65-85 years) with non-small cell lung cancer scheduled for curative lung resection. Participants are randomized 1:1 to either the intervention group, receiving a personalized exercise regimen (aerobic, resistance, and inspiratory muscle training) with continuous remote monitoring of steps, heart rate, and SpO₂ from 2-4 weeks preoperatively through 90 days postoperatively, or the control group receiving standard perioperative care. The primary endpoint is the between-group difference in FEV₁% predicted at 90 days post-surgery, adjusted for baseline. Secondary endpoints include functional capacity (6-minute walk distance), daily physical activity, hypoxemic burden (time with SpO₂\<90%, nocturnal oxygen desaturation index), patient-reported outcomes (EORTC QLQ-C30/LC13, mMRC), postoperative complications, readmission rates, days alive and at home, and safety outcomes. The target sample size is 198 participants enrolled at West China Hospital of Sichuan University. Anticipated risks include exercise-related musculoskeletal strain, fatigue, and transient cardiopulmonary symptoms, as well as mild skin reactions from devices, all managed through individualized exercise prescriptions, remote safety thresholds, and a graded response protocol.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages 65–85

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07809763 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 85 years or younger and at least 65 years old.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify